ONO-4538HSC

Phase 1Small molecule

Ono Pharmaceutical Co. Ltd

ONO-4538HSC is one of 51 small molecule programs targeting Malignant Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Solid TumorRecruiting

Advanced or Metastatic Solid TumorsActive, not recruiting

Malignant Solid TumorPreclinical

Recruiting

Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Avastin

Roche

Phase 2

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

6 4

Gemzar

Johnson & Johnson

Phase 1

2 5

Vectibix

Amgen

Phase 1

1 6

Adriamycin

Pfizer

Phase 1

1 7

Taxane

Bristol-Myers Squibb

Phase 2

1 8

Standard Treatment

Boehringer Ingelheim

Phase 2

1 9

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Phase 2

1 10

Taxotere

AAvyxa

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT06548217

Q1 2032

PreclinicalRecruiting

Malignant Solid Tumor

NCT07734116

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

An Open-label, Uncontrolled, Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06548217·31 enrolled

Malignant Solid Tumor1 trial

A Multicenter, Open-label, Uncontrolled Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma, and to Evaluate the Tolerability in Pediatric Patients.

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Preclinical·NCT07734116·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ONO-4538HSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONO-4538HSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONO-4538HSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ono Pharmaceutical Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ono Pharmaceutical Co. Ltd

ONO-4538HSC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2032

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Malignant Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News